- Home
- CMBM vs BLRX Comparison
CMBM vs BLRX Comparison
Compare CMBM & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMBM | BLRX |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.6M | 12.6M |
| IPO Year | 2019 | 2010 |
Fundamental Metrics
Financial Performance| Metric | CMBM | BLRX |
|---|---|---|
| Price | $1.80 | $2.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 227.3K | 8.6K |
| Earning Date | 02-19-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $220,195,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.01 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.23 | $2.30 |
| 52 Week High | $6.80 | $7.77 |
Technical Indicators
Market Signals| Indicator | CMBM | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 69.65 | 30.34 |
| Support Level | $1.44 | N/A |
| Resistance Level | $1.81 | $3.93 |
| Average True Range (ATR) | 0.17 | 0.16 |
| MACD | 0.07 | -0.03 |
| Stochastic Oscillator | 87.01 | 3.28 |
Price Performance
Historical ComparisonAbout CMBM Cambium Networks Corporation
Cambium Networks Corp provides wireless broadband networking infrastructure solutions for network operators, including medium-sized wireless Internet service providers, enterprises, and government agencies. The company geographically operates in North America; Europe, Middle East and Africa; Caribbean and Latin America; and Asia Pacific. It derives maximum revenue from North America.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.